In 3Q10, Orencia had annualized sales of $740M, of which $550M was in the US. Orencia was approved by the FDA in Dec 2005. The annual growth rate is in the low teens.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.